Skip to main content

    Vi uppgraderar Mina sidor under maj

    Boka, videobesök och chatt fungerar som vanligt i HLTHY medan vi bygger nästa version av Mina sidor.

    Öppna HLTHY för bokning, video och chatt
    The obesity clinic
    Menu closed
    Weight-Loss Medicines
    Sweden
    GLP-1
    +1

    Medical guide

    Weight-Loss Medicines in Sweden 2026: A Complete Guide

    Which weight-loss medicines are relevant in Sweden in 2026? This guide reviews approved options, key differences between medicines and what matters for access, pricing and medical fit.

    minutes reading time

    11 min

    Updated

    16 May 2026

    Reviewed by

    Dr. Dorél Lehrer

    Content

    Rx education

    Weight-loss medicines available in Sweden in 2026

    Dr. Dorél Lehrer

    Licensed Physician

    Quick answer

    In Sweden in 2026, the most important obesity medicines are GLP-1-based treatments such as Wegovy and dual-agonist treatment such as Mounjaro. The right choice depends on medical eligibility, tolerability, availability, cost and treatment goals.

    DD

    Dr. Dorél Lehrer

    Licensed Physician

    Medical Director at Viktenheten
    Experienced in medical weight management

    Verifierad av Socialstyrelsen

    Medicinskt granskad: 4 April 2026

    Medical information, not medicine advertising

    This article is educational and does not replace individual care. Which medicine may be relevant is decided by a licensed doctor after medical assessment. Prescription issuing is included only when a doctor decides it is medically appropriate.

    Medicinskt granskad av Dr. Dorél Lehrer, 4 April 2026. Innehållsrisk: rx-education.

    People looking for weight-loss medicines often meet a confusing mix of brand names, diabetes medicines and old myths about what is or is not available. A good overview starts with the approved indications and then looks at the practical differences.

    Which medicines are relevant in Sweden in 2026?

    The strongest current focus is on GLP-1-based and dual-agonist obesity medicines with meaningful clinical data for appetite regulation and weight loss.

    How Wegovy and Mounjaro differ

    They differ in active substance, dose escalation, average study outcomes, side-effect profile and how individual patients respond over time.

    What is not approved for obesity?

    Not every medicine discussed online is approved specifically for obesity, which is why off-label assumptions should be treated carefully.

    How access and pricing work

    Prescription access still depends on medical assessment, while the final practical choice is often shaped by cost, supply and follow-up model.

    Sources and Further Reading

    Denna artikel är medicinsk information skriven av Dr. Dorél Lehrer, Licensed Physician. Eventuell behandling sker efter individuell bedömning av legitimerad läkare.

    Read about medical assessment

    Related Articles

    Keep learning

    View all articles

    Discover more

    Care Program

    Read about our medical weight treatment programme

    FAQ

    Answers to common questions about GLP-1

    Book appointment

    Book a doctor consultation for weight treatment